Source: streetinsider

Press Release: Vertex Pharmaceuticals : Vertex Announces Positive Phase 1 & Phase 2 Data from Three Different Triple Combination Regimens in People with Cystic Fibrosis Who Have One F508del Mutation and One Minimal Function Mutation (F5

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive data from Phase 1 and Phase 2 studies of three different triple combination regimens in people with cystic fibrosis (CF) who have one F508del mutation and one minimal function mutation (F508del/Min). These are the first data to demonstrate the potential to treat the underlying cause of CF in these patients, who have a severe and difficult-to-treat type of the disease.

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Based on data from Vertex's latest SEC filings

Annual Revenue

Based on data from Vertex's latest SEC filings


Reshma Kewalramani's photo - President & CEO of Vertex

President & CEO

Reshma Kewalramani

CEO Approval Rating


Vertex is a biotechnology company that develops and commercializes drugs for the treatment of cystic fibrosis.

Vertex's h...
Read more